Oligonucleotide Synthesis: Unleashing The Future of Medicine

Oligonucleotides or oligos are short single stranded fragments of DNA or RNA molecules. These typically consist of 10-50 nucleotide chains with each chain made up of phosphate group, a sugar molecule (deoxyribose in DNA and ribose in RNA), and a nitrogenous base. The nitrogenous base can be adenine (A), cytosine (C), guanidine (G) and thymine (T) in DNA, or adenine (A), cytosine (C), guanidine (G) and uracil (U) in RNA. These molecules play a crucial role in genetic testing, molecular testing and various other analytical testing procedures, such as artificial gene synthesis and polymerase chain reactions.  With the approval of the first antisense oligonucleotide drug, Vitravene, the applications of oligonucleotides in research and diagnostics, in addition to therapeutics, have significantly increased. Several preclinical and clinical studies have demonstrated the potential of oligonucleotides as a safe and effective treatment modality; these molecules possess unique characteristics, such as high target specificity and superior pharmacokinetic profile. Presently, over 15 oligonucleotide-based therapies have been approved globally. Notable examples of recently approved products include (in reverse chronological order of year of approval) Amvuttra (2022), AMONDYS 45 (2021), Leqvio (2021) and Oxlumo (2020).   Additionally, close to 300 clinical studies are currently evaluating around 80 oligonucleotides for over 102 different indications across 14 therapeutic areas, targeting 66 different genes.

However, oligonucleotide synthesis is a cost-intensive and complex process that requires multidisciplinary expertise. Thus, given the growing demand for oligonucleotides and technical complexities associated with their manufacturing, drug developers are increasingly relying on oligonucleotide synthesis providers to leverage their expertise and optimize overall cost.

Visit: https://www.rootsanalysis.com/reports/microbiome-contract-manufacturing/306.html

Oligonucleotide Synthesis Market

According to Roots Analysis, the oligonucleotide synthesis market is estimated to be USD 4.8 billion in 2024 and is anticipated to grow at a CAGR of 9.9% till 2035. In terms of type of oligonucleotide, antisense oligonucleotides are anticipated to capture the highest share in oligonucleotide synthesis market by 2035. Further, amongst the key geographical regions, 42% of the global market of oligonucleotide synthesis market is anticipated to be captured by players based in North America, in 2035. 

Growth of oligonucleotide synthesis market is driven by several factors, such as growing demand for oligonucleotide-based therapies, ongoing technological advancements and increased extent of outsourcing.

Browse More Related Reports:

AI in Drug Discovery Market

https://www.rootsanalysis.com/reports/ai-based-drug-discovery-market.html

AI In Oncology Market

https://www.rootsanalysis.com/reports/ai-in-oncology-market.html

Antiviral Drugs Market

https://www.rootsanalysis.com/reports/antiviral-drugs-market.html

Aptamers Market

https://www.rootsanalysis.com/reports/aptamers-therapeutics-technologies-and-services-market.html

At Home Testing Kits Market

https://www.rootsanalysis.com/reports/self-testing-kits-market.html

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.
Contact:
Ben Johnson
+1 (415) 800 3415
[email protected]